Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Correlates of protection from SARS-CoV-2 infection
Florian Krammer
The Lancet (2021) Vol. 397, Iss. 10283, pp. 1421-1423
Open Access | Times Cited: 117

Showing 1-25 of 117 citing articles:

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
Moriah Bergwerk, Tal Gonen, Yaniv Lustig, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 16, pp. 1474-1484
Open Access | Times Cited: 1364
The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic
Markus Hoffmann, Nadine Krüger, Sebastian Schulz, et al.
Cell (2021) Vol. 185, Iss. 3, pp. 447-456.e11
Open Access | Times Cited: 870
SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients
Daryl Geers, Marc C. Shamier, Susanne Bogers, et al.
Science Immunology (2021) Vol. 6, Iss. 59
Open Access | Times Cited: 520
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
Ann R. Falsey, Magdalena E. Sobieszczyk, Ian Hirsch, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 25, pp. 2348-2360
Open Access | Times Cited: 381
Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2
Sam Afkhami, Michael R. D’Agostino, Ali Zhang, et al.
Cell (2022) Vol. 185, Iss. 5, pp. 896-915.e19
Open Access | Times Cited: 265
SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity
Stefan Pilz, Verena Theiler‐Schwetz, Christian Trummer, et al.
Environmental Research (2022) Vol. 209, pp. 112911-112911
Open Access | Times Cited: 233
A correlate of protection for SARS-CoV-2 vaccines is urgently needed
Florian Krammer
Nature Medicine (2021) Vol. 27, Iss. 7, pp. 1147-1148
Open Access | Times Cited: 201
Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses
David M. Morens, Jeffery K. Taubenberger, Anthony S. Fauci
Cell Host & Microbe (2023) Vol. 31, Iss. 1, pp. 146-157
Open Access | Times Cited: 128
Risk and severity of SARS-CoV-2 reinfections during 2020–2022 in Vojvodina, Serbia: A population-level observational study
Snežana Medić, Cleo Anastassopoulou, Zagorka Lozanov-Crvenković, et al.
The Lancet Regional Health - Europe (2022) Vol. 20, pp. 100453-100453
Open Access | Times Cited: 79
Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?
Gregory Milne, Thomas Hames, Chris J. Scotton, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 12, pp. 1450-1466
Open Access | Times Cited: 79
BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study
Galia Rahav, Yaniv Lustig, Jacob Lavee, et al.
EClinicalMedicine (2021) Vol. 41, pp. 101158-101158
Open Access | Times Cited: 78
Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine
Yuxin Chen, Shengxia Yin, Xin Tong, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 3, pp. 410-418
Open Access | Times Cited: 77
Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge
Antonio E. Muruato, Michelle N. Vu, Bryan A. Johnson, et al.
PLoS Biology (2021) Vol. 19, Iss. 11, pp. e3001284-e3001284
Open Access | Times Cited: 71
Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis
Monika Strengert, Matthias Becker, Gema Morillas Ramos, et al.
EBioMedicine (2021) Vol. 70, pp. 103524-103524
Open Access | Times Cited: 65
Immunogenicity and safety of the BNT162b2 mRNA COVID‐19 vaccine in haematopoietic stem cell transplantation recipients
Noga Shem‐Tov, Ronit Yerushalmi, Ivetta Danylesko, et al.
British Journal of Haematology (2021) Vol. 196, Iss. 4, pp. 884-891
Open Access | Times Cited: 65
The Omicron variant is highly resistant against antibody-mediated neutralization – implications for control of the COVID-19 pandemic
Markus Hoffmann, Nadine Krüger, Sebastian Schulz, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 64
The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine
Sivan Gazit, Roei Shlezinger, Galit Perez, et al.
Annals of Internal Medicine (2022) Vol. 175, Iss. 5, pp. 674-681
Open Access | Times Cited: 53
Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates
Flavia Chiuppesi, Vu H. Nguyen, Yoonsuh Park, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 50
Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals
Nicolás A. Muena, Tamara García‐Salum, Catalina Pardo‐Roa, et al.
EBioMedicine (2022) Vol. 78, pp. 103972-103972
Open Access | Times Cited: 45
SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies
Prerna Arora, Lu Zhang, Nadine Krüger, et al.
Cell Host & Microbe (2022) Vol. 30, Iss. 8, pp. 1103-1111.e6
Open Access | Times Cited: 45
Development of a T cell-based immunodiagnostic system to effectively distinguish SARS-CoV-2 infection and COVID-19 vaccination status
Esther Dawen Yu, Eric Wang, Emily Garrigan, et al.
Cell Host & Microbe (2022) Vol. 30, Iss. 3, pp. 388-399.e3
Open Access | Times Cited: 41
Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates
Vincent Pavot, Catherine Berry, Michael Kishko, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 41
Age and sex associations of SARS-CoV-2 antibody responses post BNT162b2 vaccination in healthcare workers: A mixed effects model across two vaccination periods
Cleo Anastassopoulou, Dimitra Antoni, Yiannis Manoussopoulos, et al.
PLoS ONE (2022) Vol. 17, Iss. 4, pp. e0266958-e0266958
Open Access | Times Cited: 38
Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine
Bruna Lo Sasso, Luisa Agnello, Rosaria Vincenza Giglio, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 37
Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients
Juan Manuel Carreño, Hala Alshammary, Gagandeep Singh, et al.
EBioMedicine (2021) Vol. 73, pp. 103626-103626
Open Access | Times Cited: 48
Page 1 - Next Page

Scroll to top